Table 1.
Sampling-adjusted data describing antibody levels measured by the GST-L1 assay among HPV-unvaccinated women in the Costa Rica Vaccine Trial
| HPV type | Min (MFI) | Max (MFI) | Geometric mean (MFI) | Q1* (MFI) | Q2*, median (MFI) | Q3* (MFI) | |
|---|---|---|---|---|---|---|---|
| HPV 16 |
All women (N = 2,786) |
0 |
5979 |
19 |
5 |
30 |
67 |
| Seropositive women (N = 140) |
415 |
5979 |
902 |
570 |
777 |
1329 |
|
| HPV16 infection (N = 211) |
0 |
1709 |
28 |
8 |
40 |
104 |
|
| No HPV16 infection (N = 2575) |
0 |
5979 |
18 |
5 |
30 |
66 |
|
| HPV18 | All women (N = 2,979) |
0 |
2849 |
17 |
3 |
26 |
57 |
| Seropositive women (N = 155) |
416 |
2849 |
677 |
528 |
528 |
930 |
|
| HPV18 infection (N = 196) |
0 |
2696 |
17 |
9 |
24 |
33 |
|
| No HPV18 infection (N = 2783) | 0 | 2849 | 17 | 3 | 26 | 57 |
*Q1, Q2, and Q3 refer to the first, second, and third quartiles, respectively, of the sampling-adjusted distribution of antibody levels.
“Infection” refers to incident infection over 4 years of follow-up. Analyses are based on 467 women for HPV16 and 477 women for HPV18; displayed sample sizes are sampling-adjusted.